Stock comparison
Glaukos
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GKOS
Glaukos
Market cap
$7.06B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GKOS | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 21F | 75B | IDXX |
| Benjamin Graham | 56D | 80A | IDXX |
| Philip Fisher | 44D | 75B | IDXX |
| Peter Lynch | 29F | 71B | IDXX |
| Joel Greenblatt | 2F | 83C | IDXX |
| Charlie Munger | 30F | 87A | IDXX |
| Terry Smith | 30F | 84A | IDXX |
Side-by-side metrics
| Metric | GKOS | IDXX |
|---|---|---|
| Market cap | $7.06B | $44.12B |
| P/E (TTM) | - | 39.0x |
| EV/EBIT | - | 31.6x |
| ROIC (TTM) | -10.4% | 40.66% |
| Gross margin | 78.08% | 62.05% |
| Net margin | -34.34% | 24.63% |
| Revenue CAGR 5y | 14.62% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 0.2x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GKOS leads on
- P/E (TTM)-vs 39.0x+188%
- EV/EBIT-vs 31.6x+132%
- Debt / Equity0.2xvs 0.7x+78%
- Revenue CAGR 5y14.62%vs 7.56%+48%
IDXX leads on
- Net margin24.63%vs -34.34%+172%
- ROIC (TTM)40.66%vs -10.4%+126%
- Market cap$44.12Bvs $7.06B+84%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.